Back to search results
NCT04040062

Spectral TMS (s-TMS)

Enrolling by Invitation
NAAges 18–65InterventionalTreatment
University of California, Los Angeles
~10 participants
Updated 2026-03-18 on ClinicalTrials.gov
What's tested:Transcranial Magnetic Stimulation

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Inventory of Depressive Symptoms- Self report
Measured over Weekly

Conditions

Major Depressive Disorder

Explore related trials

Unipolar Depression

Where it's being run

1 sites across 1 states
California1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All subjects must be over between 18-65 years of age.
Must have confirmed diagnosis of severe Major Depressive Disorder (single or recurrent episode).
Failure to respond to a minimum of 4 trials of antidepressant medication
Failure to respond from at least two different agent classes
Accompanied by at least two evidence-based augmentation therapies (Benzodiazepines do not count).
Must have a trial of psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration.
Subjects are willing and able to adhere to the treatment schedule and required study visits

Exclusion

Are mentally or legally incapacitated, unable to give informed consent
Have an infection or poor skin condition over the scalp where the device will be positioned
Have increased risk of seizure because of family history, stroke, or currently use medications that lead to increased risk for seizure
Diagnosis of acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode.
Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system.
Presence of an implanted magnetic-sensitive medical device located less than or equal to 30 centimeters from the transcranial magnetic stimulation magnetic coil or other implanted metal items, including but not limited to a cochlear implant, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents.

What this trial measures

  • Inventory of Depressive Symptoms- Self reportWeekly

    This survey is designed to assess the severity of depressive symptoms. The IDS assess all the criterion symptom domains designated by the American PsychiatryAssociation Diagnostic and Statistical Manual of Mental Disorders - 4th edition (DSM-IV) (APA1994) to diagnose a major depressive episode. These assessments can be used to screen fordepression, although they have been used predominantly as measures of symptom severity. The seven day period prior to assessment is the usual time frame for assessing symptom severity.